Treatment with dapagliflozin led to a statistically significant improvement in HbA1c compared with placebo. The Food and Drug Administration (FDA) has expanded the approval of Farxiga ® (dapagliflozin ...

AstraZeneca AZN announced that the FDA granted label expansion to its blockbuster drug Farxiga (dapagliflozin) to treat pediatric patients aged 10 years and older with type-2 diabetes (T2D). Farxiga ...

WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca’s FARXIGA ® (dapagliflozin) has been approved by the US Food and Drug Administration (FDA) to improve glycemic control in pediatric patients with type-2 ...

Farxiga can cost between $400 and $600 without insurance, depending on the pharmacy and whether a person buys the brand drug or the generic. Whether Medicare can pay a share of this cost depends on ...

Astrazeneca plc followed up its win a year ago in heart failure (HF) with yet another approval for its oral SGLT2 inhibitor, Farxiga (dapagliflozin), now cleared by the FDA to reduce the odds of ...

Just over a year since AstraZeneca announced topline results, the FDA has approved a label expansion to include reducing cardiovascular (CV) death and heart failure–related hospitalizations for ...

Results from the DELIVER and DAPA-HF Phase III trials demonstrate FARXIGA’s efficacy in heart failure regardless of ejection fraction WILMINGTON, Del.--(BUSINESS WIRE)-- High-level results from the ...

Maryland’s prescription drug affordability board (PDAB) passed resolutions affirming that Eli Lilly and Boehringer Ingelheim’s Jardiance (empagliflozin) and AstraZeneca’s Farxiga (dapagliflozin) carry ...

Comparative effectiveness study followed adults with type 2 diabetes who initiated SGLT-2 inhibitors from 2014 to 2020. Real-world outcomes largely point to comparable risks of hospitalization for ...

Dapagliflozin (Farxiga) appears to be no more effective than the "thiazide-like" diuretic metolazone at improving pulmonary congestion and fluid status in patients with acute heart failure (AHF), ...